NDA 020717 · Nuvo Pharms
Provigil
Modafinil · Oral · Sympathomimetic-like Agent
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jan 15, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Dec 24, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
214
53 Phase 3, 7 recruiting
FAERS reports
32,343
18,783 serious, 1,083 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 16, 2026.
PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating and during treatment with PROVIGIL for excessive sleepiness. PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). ( 1 ) Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.
Mechanism: The mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although the pharmacologic profile is not identical to that of the sympathomimetic amines. Modafinil-induced wakefulness can be attenuated by the α1-adrenergic receptor antagonist, prazosin; however, modafinil is inactive in other in vitro assay systems known to be responsive to α-adrenergic agonists such as the rat vas deferens preparation. Modafinil is not a direct- or indirect-acting dopamine receptor...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 2004 Supplement 8 · Efficacy LabelLetter
- Dec 24, 1998 Original approval · Type 1 - New Molecular Entity ReviewPediatric Medical ReviewPediatric Written Request
2 products under this application
- PROVIGIL · MODAFINIL 200MG · TABLET, ORAL · Prescription · TE AB
- PROVIGIL · MODAFINIL 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Modafinil" as an intervention, any sponsor and status, largest first.
- Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingTerminated
CephalonIndustry
NCT01121536 · 867 participants · Start Apr 30, 2010 · Primary completion Oct 31, 2013
Drug: Armodafinil · For: Depression
Sites: Birmingham, Alabama; Anaheim, California; Cerritos, California · 158 sites in all
- Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for CancerPivotal-lookingCompleted
Gary MorrowAcademic, hospital or other
NCT00042848 · 837 participants (planned) · Start Aug 2002 · Primary completion Apr 2007
Drug: modafinil · For: Fatigue; Unspecified Adult Solid Tumor, Protocol Specific
Sites: Mobile, Alabama; Phoenix, Arizona; Santa Rosa, California · 35 sites in all
- RECOVER-SLEEP: Platform ProtocolPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT06404086 · 830 participants · Start Jul 31, 2024 · Primary completion Dec 31, 2025
Drug: Modafinil; Modafinil Placebo and 4 more · For: Long COVID; Long COVID-19; Hypersomnia and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Palo Alto, California · 47 sites in all
- Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingCompleted
CephalonIndustry
NCT01072630 · 492 participants · Start Mar 2010 · Primary completion Nov 2012
Drug: Armodafinil; Placebo · For: Depression
Sites: Birmingham, Alabama; Anaheim, California; Cerritos, California · 92 sites in all
- A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingCompleted
CephalonIndustry
NCT01072929 · 433 participants · Start Jan 2010 · Primary completion Mar 2012
Drug: Armodafinil; Placebo · For: Depression
Sites: Birmingham, Alabama; Beverly Hills, California; Garden Grove, California · 40 sites in all
- Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag DisorderPivotal-lookingCompleted
CephalonIndustry
NCT00758498 · 427 participants · Start Sep 2008 · Primary completion Feb 2009
Drug: armodafinil; armodafinil and 1 more · For: Excessive Sleepiness
Sites: Atlanta, Georgia; Crestview, Kentucky; New York, New York · 4 sites in all
- Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingCompleted
CephalonIndustry
NCT01305408 · 399 participants · Start Mar 2011 · Primary completion Jul 2013
Drug: Armodafinil; Placebo · For: Depression
Sites: Birmingham, Alabama; Sherman Oaks, California; Temecula, California · 130 sites in all
- Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)Pivotal-lookingCompleted
CephalonIndustry
NCT00078325 · 395 participants · Start Feb 2004 · Primary completion Nov 2004
Drug: Armodafinil 250 mg/day; Armodafinil 150 mg/day and 1 more · For: Obstructive Sleep Apnea; Hypopnea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,978
- nausea2,286
- drug ineffective2,177
- headache1,894
- fall1,807
- depression1,631
- anxiety1,523
- somnolence1,438
- dizziness1,426
- pain1,306
- insomnia1,169
- condition aggravated1,139
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 332 |
| 2005 | 474 |
| 2006 | 441 |
| 2007 | 570 |
| 2008 | 787 |
| 2009 | 706 |
| 2010 | 781 |
| 2011 | 975 |
| 2012 | 1,009 |
| 2013 | 801 |
| 2014 | 1,045 |
| 2015 | 2,421 |
| 2016 | 5,872 |
| 2017 | 2,523 |
| 2018 | 2,558 |
| 2019 | 2,338 |
| 2020 | 1,880 |
| 2021 | 1,267 |
| 2022 | 1,338 |
| 2023 | 1,328 |
| 2024 | 1,274 |
| 2025 | 962 |
| 2026 | 661 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Provigil (Modafinil)
2024 spending
$13.2M
Beneficiaries
494
2,880 claims
Per beneficiary
$26,748
$72.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,518,344 |
| 2021 | $16,596,906 |
| 2022 | $14,549,020 |
| 2023 | $13,163,337 |
| 2024 | $13,213,729 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S, Adamo N, Del Giovane C, et al. · Lancet Psychiatry 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J, Johnston A, Husereau D, et al. · PLoS One 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Multiple sclerosis.
Nicholas R, Rashid W · BMJ Clin Evid 2012 · Systematic Review
- Multiple sclerosis.
Nicholas R, Chataway J · BMJ Clin Evid 2009 · Systematic Review
Sponsor: Nuvo Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.